Title:Thiazole, Isatin and Phthalimide Derivatives Tested in vivo against
Cancer Models: A Literature Review of the Last Six Years
Volume: 31
Issue: 20
Author(s): Aline Ferreira Pinto, Janine Siqueira Nunes, José Eduardo Severino Martins, Amanda Calazans Leal, Carla Cauanny Vieira Costa Silva, Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olímpio, Elineide Tayse Noberto da Silva, Thiers Araújo Campos and Ana Cristina Lima Leite*
Affiliation:
- Laboratory of Planning in Medicinal Chemistry, Department of Pharmaceutical Sciences, Center for Health
Sciences, Federal University of Pernambuco, 50740-520, Recife, PE, Brazil
Keywords:
Thiazole, isatin, phthalimide, cancer, animal model, in vivo, clinical trial.
Abstract:
Background: Cancer is a disease characterized by the abnormal multiplication
of cells and is the second leading cause of death in the world. The search for new effective
and safe anticancer compounds is ongoing due to factors such as low selectivity, high toxicity,
and multidrug resistance. Thus, heterocyclic compounds derived from isatin, thiazole
and phthalimide that have achieved promising in vitro anticancer activity have been
tested in vivo and in clinical trials.
Objective: This review focused on the compilation of promising data from thiazole, isatin,
and phthalimide derivatives, reported in the literature between 2015 and 2022, with in vivo
anticancer activity and clinical trials.
Methods: A bibliographic search was carried out in the PUBMED, MEDLINE, ELSEVIER,
and CAPES PERIODIC databases, selecting relevant works for each pharmacophoric
group with in vivo antitumor activity in the last 6 years.
Results: In our study, 68 articles that fit the scope were selected and critically analyzed.
These articles were organized considering the type of antitumor activity and their year of
publication. Some compounds reported here demonstrated potent antitumor activity
against several tumor types.
Conclusion: This review allowed us to highlight works that reported promising structures
for the treatment of various cancer types and also demonstrated that the privileged structures
thiazole, isatin and phthalimide are important in the design of new syntheses and
molecular optimization of compounds with antitumor activity.
